PD-1抗体与抗血管生成药物分别联合化疗治疗晚期驱动基因阴性肺腺癌的近远期效果对比OACSTPCD

Objective:To compare the short-term and long-term effects of programmed cell death receptor-1(PD-1)antibody or anti-angiogenic drug combined with chemotherapy in the treatment of driver gene-negative advanced lung adenocarcinoma.Methods:118 patients with driver gene-negative advanced lung adenocarcinoma were selected as the research subjects,they were divided into group A(treated with PD-1 antibody combined with chemotherapy,n=60)and group B(treated with anti-angiogenic drug combined with chemotherapy,n=58)according to different treatment methods.The short-term clinical efficacy,toxic and side effects,immune function and prognosis were observed in both groups.Results:In terms of short-term clinical efficacy,the objective response rate(ORR),disease control rate(DCR)and progression-free survival(PFS)were higher in group A after treatment compared to group B(P＜0.05).After treatment,the levels of CD3+,CD4+and CD4+/CD8+in both groups were risen compared with those before treat-ment(P＜0.05),and the levels in group A were higher than those in group B(P＜0.05).The level of CD8+was reduced in the two groups after treatment than that before treatment,and the CD8+in group A was lower than that in group B(P＜0.05).There were no obvious differences in the toxic and side effects between A groups and B groups during treatment(P>0.05).Conclusion:PD-1 anti-body combined with chemotherapy has good clinical efficacy in treating patients with driver gene-negative advanced lung adenocarcino-ma.It can help to restore theimmune function,and it has few toxic and side effect and good safety and is helpful to prolong PFS,which is worthy of clinical promotion and application.